Innovative Oncology Focus Beta Pharma specializes in emerging late-stage therapies targeting oncology, positioning them as a key partner for organizations seeking cutting-edge cancer treatment solutions.

Growing Product Pipeline With a diverse and rapidly developing pipeline, Beta Pharma offers opportunities for collaboration on novel therapies at various clinical stages, appealing to partners interested in early to late-stage drug development.

Mid-Sized Market Presence Operating with 11 to 50 employees and generating revenues between 25M to 50M dollars, Beta Pharma presents a nimble yet growing company ready for strategic partnerships and investment.

Established Development Milestones The successful Phase I trial and ongoing global registration of Icotinib demonstrate Beta Pharma's capability to bring new medicines through critical regulatory pathways, indicating potential for future licensing or acquisition deals.

Potential for Industry Collaboration Sharing similarities with large pharma firms in oncology and having a proven track record in clinical advancement, Beta Pharma is an attractive partner for corporations seeking innovative oncology assets and joint development opportunities.